Cargando…
Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis
BACKGROUND: Diabetes is prevalent among people with CF (PwCF) and associated with worse clinical outcomes. CFTR modulators are highly effective in improving the disease course of CF. However, the effects of elexacaftor/tezacaftor/ivacaftor (ETI) on glucose metabolism in PwCF are unclear. METHODS: Tw...
Autores principales: | Chan, Christine L., Granados, Andrea, Moheet, Amir, Singh, Sachinkumar, Vigers, Timothy, Arbeláez, Ana Maria, Yi, Yaling, Hu, Shanming, Norris, Andrew W., Ode, Katie Larson |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816065/ https://www.ncbi.nlm.nih.gov/pubmed/36620757 http://dx.doi.org/10.1016/j.jcte.2022.100311 |
Ejemplares similares
-
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021) -
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety
in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022) -
ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020) -
Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
por: Causer, Adam J., et al.
Publicado: (2022) -
Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
por: Cavinato, Luca, et al.
Publicado: (2023)